Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term phase 3 study of subcutaneous efgartigimod PH20 in adults with primary immune thrombocytopenia
CTR20211920Phase 3Active
- Sponsor
- argenx
- Start
- Apr 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa in immune thrombocytopenia (ITP), sponsored by argenx. Started Apr 2022; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20211920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211920.